Strategic Partnerships ARIZ offers a preclinical platform targeting PRDM-driven cancers with proprietary siRNA constructs and advanced drug delivery nanotechnologies, presenting a clear path to clinic through strategic pharma partnerships and licensing deals.

Broad Platform Value The technology demonstrates selective killing of cancer cells with PRDM abnormalities across multiple tumor types while sparing normal cells, providing broad collaboration potential for oncology programs seeking targeted therapies and reduced toxicity.

Delivery Edge Proprietary nanodelivery solutions combined with gene-targeting biology offer a differentiated value prop that could integrate with existing pipelines and create joint development opportunities with pharma partners.

Early Traction Signals Evidence of market validation and external funding raises interest for co-development or sponsored research, making ARIZ a compelling early-stage partner for drug discovery collaborations.

Leadership IP Momentum Leadership with deep PRDM expertise and a focused IP strategy, supported by a board of drug delivery and development veterans, enhances partner diligence and de-risks early negotiations.